Nothing Special   »   [go: up one dir, main page]

SI1558219T1 - Farmacevtska formulacija olanzapina - Google Patents

Farmacevtska formulacija olanzapina

Info

Publication number
SI1558219T1
SI1558219T1 SI200331001T SI200331001T SI1558219T1 SI 1558219 T1 SI1558219 T1 SI 1558219T1 SI 200331001 T SI200331001 T SI 200331001T SI 200331001 T SI200331001 T SI 200331001T SI 1558219 T1 SI1558219 T1 SI 1558219T1
Authority
SI
Slovenia
Prior art keywords
olanzapine
pharmaceutical formulation
monosaccharide
oligosaccharide
polysaccharide
Prior art date
Application number
SI200331001T
Other languages
English (en)
Inventor
Stanka Perc
Ivanka Banko
Ivanka Kolenc
Original Assignee
Krka, Tovarna Zdravil, D.D, Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32173824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1558219(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka, Tovarna Zdravil, D.D, Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D, Novo Mesto
Publication of SI1558219T1 publication Critical patent/SI1558219T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI200331001T 2002-10-18 2003-10-16 Farmacevtska formulacija olanzapina SI1558219T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200200255A SI21303A (sl) 2002-10-18 2002-10-18 Farmacevtska formulacija olanzapina
EP03751723A EP1558219B1 (en) 2002-10-18 2003-10-16 Pharmaceutical formulation of olanzapine
PCT/SI2003/000036 WO2004035027A1 (en) 2002-10-18 2003-10-16 Pharmaceutical formulation of olanzapine

Publications (1)

Publication Number Publication Date
SI1558219T1 true SI1558219T1 (sl) 2008-02-29

Family

ID=32173824

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200200255A SI21303A (sl) 2002-10-18 2002-10-18 Farmacevtska formulacija olanzapina
SI200331001T SI1558219T1 (sl) 2002-10-18 2003-10-16 Farmacevtska formulacija olanzapina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200200255A SI21303A (sl) 2002-10-18 2002-10-18 Farmacevtska formulacija olanzapina

Country Status (18)

Country Link
US (2) US20050288276A1 (sl)
EP (1) EP1558219B1 (sl)
AT (1) ATE374600T1 (sl)
AU (1) AU2003269792A1 (sl)
CA (1) CA2502582C (sl)
CY (1) CY1107819T1 (sl)
DE (1) DE60316714T2 (sl)
DK (1) DK1558219T3 (sl)
EA (1) EA008516B1 (sl)
ES (1) ES2295626T3 (sl)
HR (1) HRP20050342B1 (sl)
NO (1) NO20052408L (sl)
PL (1) PL206217B1 (sl)
PT (1) PT1558219E (sl)
RS (1) RS51488B (sl)
SI (2) SI21303A (sl)
UA (1) UA89349C2 (sl)
WO (1) WO2004035027A1 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778183B1 (en) * 2004-08-18 2018-06-27 Synthon B.V. Liquid paroxetine compositions
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2083622B1 (sl) * 1970-03-27 1975-08-22 Sankyo Co
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
HUP9904065A3 (en) * 1996-09-24 2001-10-29 Lilly Co Eli Coated particle formulations containing olanzapine
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2003055438A2 (en) * 2001-12-24 2003-07-10 Sun Pharmaceutical Industries Limited Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions

Also Published As

Publication number Publication date
EP1558219A1 (en) 2005-08-03
RS20050292A (en) 2007-08-03
EA200500671A1 (ru) 2005-10-27
DE60316714T2 (de) 2008-07-17
HRP20050342A2 (hr) 2006-04-30
US20050288276A1 (en) 2005-12-29
HRP20050342B1 (hr) 2013-11-08
EA008516B1 (ru) 2007-06-29
PT1558219E (pt) 2008-01-04
RS51488B (en) 2011-04-30
DK1558219T3 (da) 2007-10-29
NO20052408D0 (no) 2005-05-13
WO2004035027A1 (en) 2004-04-29
EP1558219B1 (en) 2007-10-03
DE60316714D1 (de) 2007-11-15
ATE374600T1 (de) 2007-10-15
SI21303A (sl) 2004-04-30
CY1107819T1 (el) 2013-06-19
CA2502582C (en) 2010-08-03
PL206217B1 (pl) 2010-07-30
CA2502582A1 (en) 2004-04-29
UA89349C2 (uk) 2010-01-25
AU2003269792A1 (en) 2004-05-04
PL376413A1 (en) 2005-12-27
ES2295626T3 (es) 2008-04-16
US20110319395A1 (en) 2011-12-29
NO20052408L (no) 2005-07-04

Similar Documents

Publication Publication Date Title
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
FR11C0017I1 (sl)
EP1483277A4 (en) CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS OF PREPARATION AND USE, AND FORMULATION AND PHARMACEUTICAL APPLICATIONS
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AU2003215245A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
EP2308479A3 (en) Compounds and compositions for delivering active agents
ATE292453T1 (de) Antivirale arznei
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2005065639A3 (en) Novel pharmaceutical compositions
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
IL166596A0 (en) Salt of morphine-6-glucoronide
WO2002041875A3 (de) Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen
HRP20050466A2 (en) Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?
IL163552A0 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof